Strategic partnerships Alloy serves as an integrated discovery engine for partners, with a broad ecosystem reach including 18 of the top 50 biopharma companies and collaboration with entities like Voro Therapeutics and the Institute for Protein Innovation, presenting numerous co-development and out-licensing sales opportunities.

Platform breadth The company offers in vivo and in vitro antibody and complex biologics platforms, intracellular target discovery via Keyway, RNA medicines with AntiClastic cyclic RNA, and end-to-end preclinical to clinical support, enabling cross-sell to clients seeking end-to-end development services.

Venture and spinouts 82VS, Alloy’s affiliated venture studio, signals opportunities to engage early-stage biotech ventures or spinouts seeking platform-enabled company creation, funding rounds, or strategic collaboration from inception through development milestones.

Strategic collaborations Recent and ongoing collaborations in masked T-cell engager development and tumor-selective immunotherapies with partners like Voro Therapeutics highlight a recurring demand for combination capabilities that can be packaged into joint offerings and co-development agreements.

Geographic and capability scale Founded in Boston with global operations across the US, Europe, and Japan, Alloy’s international footprint coupled with extensive AI, ML, and high-throughput platforms positions it to expand sales efforts to multinational partners needing scalable, tech-enabled discovery and development resources.